140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
V. Guarneri(University of Padua), Aleix Prat(Hospital Clínic de Barcelona), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), P. Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), P.F. Conte(Istituto Oncologico Veneto), Joel S. Parker(University of North Carolina at Chapel Hill), Patricia Galván(Vall d'Hebron Institute of Oncology), P. Villagrasa Gonzalez(Oryzon Genomics (Spain)), Charles M. Perou(University of North Carolina at Chapel Hill), Michele Bottosso(University of Padua), Ana Vivancos(Vall d'Hebron Institute of Oncology), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), M. Marin(Oryzon Genomics (Spain)), L. Pare Brunet(Oryzon Genomics (Spain)), Pedro Jares(Hospital Clínic de Barcelona), J.A. Puig‐Butillé(Hospital Clínic de Barcelona), Federica Miglietta(University of Padua)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k